Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[AFFIRM: what we have learned ... and pending issues].

J Y Le Heuzey1, E Aliot, P Jaillon

  • 1Service de cardiologie A, hôpital Européen-Georges-Pompidou, 20, rue Leblanc, 75015 Paris, France. jean-yves.le-heuzey@hop.egp.aphp.fr

Annales De Cardiologie Et D'Angeiologie
|August 18, 2005
PubMed
Summary

For atrial fibrillation, rate control is a viable first-line treatment. However, rhythm control remains preferable for patients with heart failure or young individuals without heart disease.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High prevalence of ventricular repolarization abnormalities in people carrying TGFβR2 mutations.

Scientific reports·2018
Same author

[Editorial].

Presse medicale (Paris, France : 1983)·2016
Same author

Discontinuation And Hospitalisation Rates In Patients With Atrial Fibrillation: Follow-Up Results Of The Prefer In Af Registry.

Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research·2016
Same author

Antithrombotic treatment of atrial fibrillation: new insights.

Thrombosis research·2012
Same author

[Is atrial fibrillation an independent marker of cardiovascular risk?].

Annales de cardiologie et d'angeiologie·2011
Same author

[Silent atrial fibrillation].

Annales de cardiologie et d'angeiologie·2010

Area of Science:

  • Cardiology
  • Clinical Trials
  • Electrophysiology

Context:

  • Atrial fibrillation management has evolved with therapeutic strategy trials comparing rhythm and rate control.
  • The AFFIRM study is a pivotal trial in this field, influencing current treatment guidelines.

Purpose:

  • To compare the efficacy of rhythm control (sinus rhythm maintenance) versus rate control (heart rate slowing) in atrial fibrillation.
  • To determine the optimal first-line therapeutic strategy for atrial fibrillation management.

Summary:

  • The AFFIRM study concluded that rate control can be the initial strategy for atrial fibrillation.
  • This recommendation excludes patients with heart failure and young, otherwise healthy individuals, who benefit more from rhythm control.

Related Experiment Videos

Impact:

  • Treatment guidelines for atrial fibrillation are influenced by the AFFIRM study's findings.
  • Identifies specific patient subgroups (heart failure, young without cardiopathy) where rhythm control remains the preferred strategy.